A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

BACKGROUND: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy. PATIENTS AND METHODS: In this single-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S., Pfister, C., Haque, S., Katabi, N., Ho, A. L., Pfister, D. G.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834071/
https://ncbi.nlm.nih.gov/pubmed/28961834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx346
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares